Should I buy or sell Standard BioTools stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Standard BioTools in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LAB shares. View LAB analyst ratings or view top-rated stocks .

What is Standard BioTools' stock price target for 2024?

2 brokerages have issued 12 month price objectives for Standard BioTools' stock. Their LAB share price targets range from $3.25 to $4.00. On average, they predict the company's share price to reach $3.63 in the next year. This suggests a possible upside of 30.9% from the stock's current price. View analysts price targets for LAB or view top-rated stocks among Wall Street analysts .

How have LAB shares performed in 2024?

Standard BioTools' stock was trading at $2.21 at the start of the year. Since then, LAB shares have increased by 25.3% and is now trading at $2.77. View the best growth stocks for 2024 here .

Are investors shorting Standard BioTools?

Standard BioTools saw a increase in short interest in March. As of March 31st, there was short interest totaling 10,230,000 shares, an increase of 10.5% from the March 15th total of 9,260,000 shares. Based on an average daily trading volume, of 2,170,000 shares, the days-to-cover ratio is currently 4.7 days. Approximately 2.7% of the shares of the company are sold short. View Standard BioTools' Short Interest .

When is Standard BioTools' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our LAB earnings forecast .

How were Standard BioTools' earnings last quarter?

Standard BioTools Inc. (NASDAQ:LAB) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.05. The firm earned $28.19 million during the quarter, compared to analyst estimates of $28 million.

What ETFs hold Standard BioTools' stock?

ETFs with the largest weight of Standard BioTools (NASDAQ:LAB) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) . Invesco Nasdaq Future Gen 200 ETF (QQQS) .

What guidance has Standard BioTools issued on next quarter's earnings?

Standard BioTools updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$205.0 million.

Who are Standard BioTools' major shareholders?

Standard BioTools' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Schoolcraft Capital LLC (0.03%). Insiders that own company stock include Caligan Partners Lp, Casdin Partners Master Fund, L, Eli Casdin and Jeffrey G Black. View institutional ownership trends .

How do I buy shares of Standard BioTools?

Shares of LAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LAB

Standard BioTools (LAB) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free LAB Stock Alerts

$2.77

-0.02 (-0.72%)

(As of 04/15/2024 ET)

Compare

Today's Range: $2.72
▼
$2.86
50-Day Range: $2.25
▼
$2.92
52-Week Range: $1.46
▼
$3.16

Volume: 2.17 million shs
Average Volume: 2.63 million shs
Market Capitalization: $803.63 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.63

Get Standard BioTools alerts:

Standard BioTools MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 30.9% Upside
$3.63 Price Target
Short Interest: Bearish
2.74% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.95
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$642,500 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.47) to ($0.32) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.05 out of 5 stars

Medical Sector

427th out of 928 stocks

Analytical Instruments Industry

17th out of 28 stocks

3.5

Analyst's Opinion

Consensus Rating
Standard BioTools has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Standard BioTools has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.74% of the float of Standard BioTools has been sold short.
Short Interest Ratio / Days to Cover
Standard BioTools has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in Standard BioTools has recently increased by 10.48%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Standard BioTools does not currently pay a dividend.
Dividend Growth
Standard BioTools does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LAB.

3.3

News and Social Media Coverage

News Sentiment
Standard BioTools has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Standard BioTools this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for LAB on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
7 people have added Standard BioTools to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Standard BioTools insiders have bought more of their company's stock than they have sold. Specifically, they have bought $642,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
53.10% of the stock of Standard BioTools is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
53.74% of the stock of Standard BioTools is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Standard BioTools are expected to grow in the coming year, from ($0.47) to ($0.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Standard BioTools is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Standard BioTools is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

>>Check out what this A.I. Perfect Storm is<<

About Standard BioTools Stock (NASDAQ:LAB)

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

LAB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LAB Stock News Headlines

March 16, 2024 | insidertrades.com

Standard BioTools Inc. (NASDAQ:LAB) Director Acquires $642,500.00 in Stock

April 16, 2024 | americanbankingnews.com

Standard BioTools Inc. (NASDAQ:LAB) Short Interest Update

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

April 8, 2024 | globenewswire.com

Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging

April 5, 2024 | investing.com

Standard BioTools secures deal with Bristol Myers Squibb

April 4, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Standard BioTools (LAB)

April 3, 2024 | globenewswire.com

Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research

April 2, 2024 | finance.yahoo.com

Is Now The Time To Look At Buying Standard BioTools Inc. (NASDAQ:LAB)?

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

March 29, 2024 | msn.com

Nikon, Lunaphore team up for spatial biology services

March 20, 2024 | investing.com

Standard BioTools swaps preferred for common stock

March 19, 2024 | finance.yahoo.com

Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)

March 18, 2024 | msn.com

Standard Biotools exchanges all outstanding Series B convertible preferred stock for common stock

March 18, 2024 | globenewswire.com

Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock

March 5, 2024 | finance.yahoo.com

Standard BioTools Inc. (NASDAQ:LAB) Q4 2023 Earnings Call Transcript

March 1, 2024 | seekingalpha.com

Standard BioTools Inc. (LAB) Q4 2023 Earnings Call Transcript

March 1, 2024 | finance.yahoo.com

Standard BioTools Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line

February 29, 2024 | finance.yahoo.com

Q4 2023 Standard BioTools Inc Earnings Call

February 28, 2024 | finance.yahoo.com

Standard BioTools Inc (LAB) Reports Growth and Margin Expansion in FY2023 Despite Economic ...

February 28, 2024 | globenewswire.com

Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024 | finance.yahoo.com

Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing

February 22, 2024 | globenewswire.com

Standard BioTools to Participate in Upcoming Investor Conferences

February 22, 2024 | benzinga.com

Standard BioTools Stock (NASDAQ:LAB), Short Interest Report

February 18, 2024 | msn.com

Medical lab technologist faces 25 urine-tampering charges

February 16, 2024 | finance.yahoo.com

LAB Feb 2024 0.500 put

February 15, 2024 | washingtonpost.com

CLIMATE LAB

February 14, 2024 | finance.yahoo.com

Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

See More Headlines

Receive LAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Standard BioTools and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Analytical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:LAB
CUSIP: N/A
CIK: 1162194
Web: www.fluidigm.com
Phone: (650) 266-6000
Fax: 650-871-7152
Employees: 534
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.63
High Stock Price Target: $4.00
Low Stock Price Target: $3.25
Potential Upside/Downside: +30.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.95)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-74,660,000.00
Net Margins: -70.21%
Pretax Margin: -69.78%
Return on Equity: N/A
Return on Assets: -14.45%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.45
Quick Ratio: 1.26

Sales & Book Value

Annual Sales: $106.34 million
Price / Sales: 7.56
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.85) per share
Price / Book: -1.50

Miscellaneous

Outstanding Shares: 290,120,000
Free Float: 136,065,000
Market Cap: $803.63 million
Optionable: Optionable
Beta: 1.64

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Michael Egholm Ph.D. (Age 61)
President, CEO & Director
Comp: $640.34k
Mr. Hanjoon Kim (Age 53)
Chief Operating Officer
Comp: $468.05k
Mr. Jeffrey G. Black (Age 55)
Chief Financial Officer
Dr. Shane Bowen Ph.D.
Chief Technology Officer
Mr. Adam Taich (Age 48)
Chief Strategy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Standard BioTools stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Standard BioTools in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LAB shares.
View LAB analyst ratings or view top-rated stocks.
What is Standard BioTools' stock price target for 2024?: 2 brokerages have issued 12 month price objectives for Standard BioTools' stock. Their LAB share price targets range from $3.25 to $4.00. On average, they predict the company's share price to reach $3.63 in the next year. This suggests a possible upside of 30.9% from the stock's current price.
View analysts price targets for LAB or view top-rated stocks among Wall Street analysts.
How have LAB shares performed in 2024?: Standard BioTools' stock was trading at $2.21 at the start of the year. Since then, LAB shares have increased by 25.3% and is now trading at $2.77.
View the best growth stocks for 2024 here.
Are investors shorting Standard BioTools?: Standard BioTools saw a increase in short interest in March. As of March 31st, there was short interest totaling 10,230,000 shares, an increase of 10.5% from the March 15th total of 9,260,000 shares. Based on an average daily trading volume, of 2,170,000 shares, the days-to-cover ratio is currently 4.7 days. Approximately 2.7% of the shares of the company are sold short.
View Standard BioTools' Short Interest.
When is Standard BioTools' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our LAB earnings forecast.
How were Standard BioTools' earnings last quarter?: Standard BioTools Inc. (NASDAQ:LAB) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.05. The firm earned $28.19 million during the quarter, compared to analyst estimates of $28 million.

What ETFs hold Standard BioTools' stock?: ETFs with the largest weight of Standard BioTools (NASDAQ:LAB) stock in their portfolio include ARK Genomic Revolution ETF (ARKG).Invesco Nasdaq Future Gen 200 ETF (QQQS).
What guidance has Standard BioTools issued on next quarter's earnings?: Standard BioTools updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$205.0 million.
Who are Standard BioTools' major shareholders?: Standard BioTools' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Schoolcraft Capital LLC (0.03%). Insiders that own company stock include Caligan Partners Lp, Casdin Partners Master Fund, L, Eli Casdin and Jeffrey G Black.
View institutional ownership trends.
How do I buy shares of Standard BioTools?: Shares of LAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LAB) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial